2024
03
Re-certified ‘Association for Assessment and Accreeditatin of Laboratory Animal arelnternational’(AAALAC)
04
Received IND Approval of Phase 2a clinical trial for Age-related Macular Degeneration(MFDS)
2023
02
Relocation of HQ (Rm 1010, 75, Bokji-ro, Busanjin-gu, Busan, Korea(ROK))
06
Termination of Phase 1 clinical trial for Age-related Macular Degeneration(MFDS),
09
Relocation of Business Center (Rm 1406, 33, Gwacheon-daero 7-gil, Gwacheon-si, Gyeonggi-do,korea(ROK)
12
Application of Phase 2 clinical trial for Age-related Macular Degeneration(MFDS)
12
Selected as a ‘family-friendly company’ by the Ministry of Gender Equality and Family
2022
03
Series B Funding
07
Initiation of Phase 1 clinical trial for Age-related Macular Degeneration(MFDS)
05
Certificate of Inno-Biz(Technology Innovation-Oriented Small and Medium Enterprise)
05
Received IND Approval of Phase 1 clinical trial for Age-related Macular Degeneration(MFDS)
2021
07
Application of Phase 1 clinical trial for Age-related Macular Degeneration(MFDS)
07
Ministry of Health&Welfare Korea Research Driven Hospitals
2020
09
Initiation of non-clinical toxicity test for macular degeneration eye drop treatment approval
06
Bridge Funding
06
certified‘Association for Assessment and Accreeditatin of Laboratory Animal arelnternational’(AAALAC)
05
Selected as a bio-industry core technology industry
2019
10
Business Center opened
08
Registered as a venture company
07
Series A Funding
2018
05
Relocation of HQ, R&D Center(In-dang Bio Medical Research institute, Inje University Busan Paik Hospital)
2016
01
Foundation of EYEBIOKOREA INC.